Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2000-05-11 Earnings Release
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Ad hoc-Service: MorphoSys AG Q1-2000
Earnings Release Classification · 100% confidence The document is titled 'MORPHOSYS VEROEFFENTLICHT DIE ZAHLEN FUER DAS ERSTE QUARTAL 1999' (MorphoSys publishes the figures for the first quarter 1999) and explicitly states the financial results for Q1 2000, including revenue, operating expenses, and net loss. This content structure—a brief announcement detailing key financial metrics for a specific reporting period (Q1)—is characteristic of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR) nor is it merely an announcement of a report's publication (RPA). The document length is short (1628 chars), but it contains the core results, making ER the most appropriate classification over RPA. Q1 2000
2000-05-11 German
Ad hoc-Service: MorphoSys AG Bericht99
Earnings Release Classification · 99% confidence The document is titled 'MORPHOSYS JAHRESABSCHLUSS 1999' (MorphoSys Year-End Results 1999) and provides key financial highlights for the full year 1999, including turnover increase, investment figures, operating result, net loss, and loss per share. This content structure—summarizing the full year's performance immediately following the fiscal year end—is characteristic of an Earnings Release (ER), which announces the key results before the comprehensive Annual Report (10-K) might be filed or released. Since it is a summary of period results, ER is the most appropriate classification over 10-K (which is the full official report) or IR (Interim Report, which covers shorter periods). The document length is short (1796 chars), suggesting it is the initial announcement, fitting the ER definition. FY 1999
2000-03-22 German
Ad hoc-Service: MorphoSys AG Ext.Mill
Regulatory Filings Classification · 95% confidence The document is an 'Ad-hoc Mitteilung' (Ad hoc announcement) dated March 20, 2000, detailing the extension of a collaboration agreement between MorphoSys AG and Millennium Pharmaceuticals regarding joint research on antibodies. This type of announcement, which is brief and reports on a specific corporate event (a partnership extension and associated financial/research terms), does not fit the definitions for standard periodic reports (10-K, IR), specific financial events (DIV, CAP), or management changes (MANG). It is a general corporate disclosure. Since it is a specific, material corporate event announcement that isn't covered by a more precise code (like M&A or Financing), it falls best under the general regulatory announcement category, RNS, as it is an immediate, non-scheduled disclosure.
2000-03-20 German
Ad hoc-Service: MorphoSys AG USA Inc.
Board/Management Information Classification · 99% confidence The document is a short 'Ad hoc-Service' announcement dated February 24, 2000. The content explicitly states that MorphoSys is expanding to the US market by opening a subsidiary and appointing Daniel L. Menichella as its President. This announcement concerns the establishment of a new operational entity and leadership change related to commercial efforts, which falls under management or operational expansion rather than a specific financial filing like 10-K, ER, or IR. Since it announces the appointment of a new head for the US subsidiary, it strongly relates to Board/Management Information (MANG) concerning senior operational leadership, or potentially a general regulatory announcement (RNS). Given the focus on appointing the 'Head'/'President' of the new US subsidiary, MANG is the most specific fit for announcing a key management appointment, even if it's for a new subsidiary. However, since the primary theme is the *establishment* of the US presence and the appointment of the head, and it is a brief, ad-hoc news item, it could also be classified as a general Regulatory Filing (RNS) if MANG is reserved strictly for changes in the *parent company's* board/senior management. Given the context of appointing the head of a major new operational arm, MANG is a strong candidate. Let's re-evaluate against the definitions. MANG: 'Announcement of changes in the company's board of directors or senior management.' Appointing the President of the US subsidiary qualifies as senior management appointment. The document length is very short (1464 chars), but it is the primary content, not an announcement *of* another report, so RPA/RNS fallback is less likely unless MANG is strictly interpreted. I will classify this as MANG due to the explicit naming and appointment of the President/Head of the new entity.
2000-02-24 German
Ad hoc-Service: MorphoSys AG GPC Meilenstein
Regulatory Filings Classification · 95% confidence The document is a short 'Ad hoc-Service' announcement dated February 14, 2000, detailing a specific operational achievement: MorphoSys AG and GPC AG reaching a milestone in developing a new cancer therapy, resulting in a milestone payment. This is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It relates to a specific corporate event or development that impacts the company's operations and potential future value, but it is not a standard regulatory filing like insider trading (DIRS) or capital change (SHA). Given the nature of announcing a specific corporate development/achievement that is not covered by the more specific categories (like M&A, Dividend, or Board Change), it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous, time-sensitive corporate announcement, or potentially 'Capital/Financing Update' (CAP) if the milestone payment is significant, but RNS is the safer general category for non-standard operational news releases.
2000-02-14 German
Ad hoc-Service: MorphoSys AG HuCAL
Regulatory Filings Classification · 95% confidence The document is an 'Ad hoc-Service' announcement dated January 10, 2000, detailing a business development: the completion of a new antibody library (HuCAL-Fab) and the signing of a license agreement with Biosite Diagnostics. This type of announcement, which details specific corporate actions, partnerships, or significant operational updates outside of routine financial reporting (like earnings or annual reports), fits best under the general category for regulatory announcements that don't fit elsewhere. Since it is not a formal financial report (10-K, IR, ER), a management discussion (MDA), or a capital event (CAP, SHA), the most appropriate classification is the general regulatory filing category, RNS, as it is an 'Ad hoc' disclosure.
2000-01-10 German

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.